Supplementary Material (ESI) for Chemical Communications This journal is (c) The Royal Society of Chemistry 2009

Supporting Information for

Highly efficient synthesis of aldenamines from carboxamides by iridiumcatalyzed silane-reduction/dehydration under mild conditions

Yukihiro Motoyama, Masaharu Aoki, Naoki Takaoka, Ryuta Aoto, and Hideo Nagashima*

Institute for Materials Chemistry and Engineering, Graduate School of Engineering Sciences, Kyushu University, Kasuga, Fukuoka 816-8580, Japan

Tel & Fax: +81-92-583-7819

E-mail: nagasima@cm.kyushu-u.acjp

Contents

1. General Methods	P-S2
2. Preparation and Spectral Data of Carboxamides	P-S2
3. General Procedure for Reduction/Dehydration of Carboxamides	P-S5
4. Spectral Data of Enamines	P-S8
5. Cyclopropanation of 2b	P-S10
6. References	P-S10
7. NMR Spectra of Enamines and Cyclopropanation Product 4	P-S11

1. General Methods: All reactions were carried out under a nitrogen or argon atmosphere. Dehydrated benzene, toluene, ether, dichloromethane, tetrahydrofuran (THF) and diethylzinc in 1.0 M hexane solution were purchased from Kanto Chemical Co., Ltd., and used as received. xylene distilled under an inert atmosphere from sodium/benzophenone prior to use. was Polymethylhydrosiloxane (PMHS) and tetramethyldisiloxane (TMDS) were purchased from Gelest and used as received. Pentamethyldisiloxane was purchased from FluoroChem. Inc. Dimethylphenylsilane, triethylsilane, allyl bromide and diiodomethane were purchased from Tokyo Chemical Industry Co., Ltd. Karstedt's catalyst in 0.1 M xylene solution were purchased from Aldrich Chemical Co. Diphenylsilane was purchased from Chisso Co. ¹H and ¹³C NMR spectra were measured on JEOL GSX-270 (270 MHz), ECA 400 (395 MHz) and ECA 600 (600 MHz) spectrometers. Chemical shifts for ¹H NMR were described in parts per million downfield from tetramethylsilane as an internal standard ($\delta = 0$) in CDCl₃, unless otherwise noted. Chemical shifts for ¹³C NMR were expressed in parts per million in CDCl₃ as an internal standard ($\delta = 77.1$), unless otherwise noted. IR spectra were measured on a JASCO FT/IR-550 spectrometer. ICP-MS and HRMS analyses were performed at the Analytical Center in Institute for Materials Chemistry and Engineering, Kyushu University. Analytical thin-layer chromatography (TLC) was performed on aluminum sheets precoated with aluminum oxide (Merck, aluminum oxide 150 F₂₅₄, neutral) and glass plates precoated with silica gel (Merck, Kieselgel 60 F₂₅₄). Visualization was accomplished by acid. $(\mu_3;\eta^2;\eta^3;\eta^5-$ UV light (254)nm), anisaldehyde, and phosphomolybdic acenaphthylene) $Ru_3(CO)_7 [(ACE)Ru_3(CO)_7]^{1a,b}$ and citronellic acid N-benzyl-N-methylamide (**1h**)^{1c} prepared by the method reported previously. IrCl(CO)(PPh₃)₂,^{2a} RhCl(PPh₃)₃,^{2b} were [RhCl(cod)]₂,^{2c} Pt(dba)₂,^{2d} PtCl₂(cod),^{2e} and 1,2-bis(dimethylsilyl)ethane^{2f,g} were prepared by the literature method.

2. Preparation and Spectral Data of Carboxamides.

N,N-Diethylphenylacetamide (1a):³ This compound was prepared from phenylacetyl chloride and $Ph \longrightarrow NEt_2$ diethylamine. IR (neat) v 2973, 2933, 1639, 1455, 1428, 1280, 1132, 1074, 794, 727 Cm^{-1} ; ¹H NMR (396 MHz, CDCl₃) δ 1.09 (t, *J* = 7.2 Hz, 3H), 1.13 (t, *J* = 7.2 Hz, 3H), 3.30 (q, *J* = 7.2 Hz, 2H), 3.39 (q, *J* = 7.2 Hz, 2H), 3.70 (s, 2H), 7.20-7.36 (m, 5H); ¹³C NMR (99.5 MHz, CDCl₃) δ 12.4, 13.6, 39.5, 40.2, 41.8, 126.0, 127.9, 128.1, 135.0, 169.4; GLC (TC-1, 30 m, detection FID, column temp. 170 °C), *t*_R = 11.7 min. *N*-Methyl-*N*-phenylphenylacetamide (1b):⁴ This compound was prepared from phenylacetyl $Ph \rightarrow 0$ chloride and *N*-methylaniline. mp 60-63 °C; IR (KBr) v 3061, 3029, 1655, 1594, 1495, 1376, 1269, 1119, 773, 728 cm⁻¹; ¹H NMR (396 MHz, CDCl₃) δ 3.28 (s, 3H), 3.46 (s, 2H), 7.05 (d, *J* = 7.2 Hz, 2H), 7.12 (d, *J* = 7.7 Hz, 2H), 7.17-7.26 (m, 3H), 7.32-7.43 (m, 3H); ¹³C NMR (99.5 MHz, CDCl₃) δ 33.5, 40.8, 126.4, 127.5, 127.8, 128.2, 128.9, 129.6, 135.3, 143.8, 170.9.

4-(Phenylacethyl)morpholine (1c):⁵ This compound was prepared from phenylacetyl chloride and Ph CON \longrightarrow morpholine. IR (KBr) v 2981, 2860, 1643, 1434, 1274, 1115, 965, 762 cm⁻¹; ¹H NMR (396 MHz, CDCl₃) δ 3.40-3.51 (m, 4H), 3.64 (bs, 4H), 3.73 (s, 2H), 7.21-7.28 (m, 3H), 7.33 (dd, *J* = 7.7, 6.8 Hz, 2H); ¹³C NMR (99.5 MHz, CDCl₃) δ 40.9, 42.2, 46.6, 66.5, 66.9, 127.0, 128.6, 128.9, 134.9, 169.7; GLC (TC-1, 30 m, detection FID, column temp. 170 °C), *t*_R = 18.4 min.

4-(*n***-Hexanoyl)morpholine (1d):**⁶ This compound was prepared from hexanoyl chloride and morpholine. IR (neat) v 2957, 2857, 1644, 1430, 1271, 1245, 1115, 1030, 965, 848 cm⁻¹; ¹H NMR (396 MHz, CDCl₃) δ 0.90 (t, *J* = 7.0 Hz, 3H), 1.26-1.40 (m, 4H), 1.55-1.70 (m, 2H), 2.30 (t, *J* = 7.7 Hz, 2H), 3.42-3.50 (m, 2H), 3.58-3.71 (m, 6H); ¹³C NMR (99.5 MHz, CDCl₃) δ 14.0, 22.5, 25.0, 31.7, 33.2, 41.9, 46.1, 66.8, 67.1, 172.0; GLC (TC-1, 30 m, detection FID, column temp. 170 °C), *t*_R = 9.3 min.

6-Bromo-1-(morpholine-4-yl)-hexan-1-one (1e):⁷ This compound was prepared from 6bromohexanoyl chloride and morpholine. IR (neat) v 2929, 2856, 1646, 1431, 1272, 1228, 1115, 1031, 848 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 1.42- 1.58 (m, 2H), 1.59-1.75 (m, 2H), 1.82-1.96 (m, 2H), 2.33 (t, *J* = 7.4 Hz, 2H), 3.36-3.71 (m, 10H); ¹³C NMR (99.5 MHz, CDCl₃) δ 24.3, 28.0, 32.6, 32.8, 33.7, 42.0, 46.0, 66.7, 67.0, 171.4.

N-Benzyl-N-methyl-7-carbomethoxyheptanamide (1f):⁸ This compound was prepared from MeO₂C NBnMe suberic acid monomethyl ester and pivaloyl chloride followed by the reaction with benzylmethylamine. IR (KBr) v 2937, 2863, 1734, 1651, 1452, 1205, 1171, 1080, 733 cm⁻¹. Spectroscopic data of this amide were obtained as a mixture of two rotational isomers. *major isomer:* ¹H NMR (395 MHz, CDCl₃) δ 1.23-1.50 (m, 4H), 1.53-1.81 (m, 4H), 2.21-2.47 (m, 4H), 2.90 (s, 3H), 3.66 (s, 3H), 4.59 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz, CDCl₃) δ 24.8, 25.0, 29.0, 29.1, 33.5, 34.02, 34.04, 50.8, 51.5, 126.3, 128.0, 128.6, 137.6, 173.1, 174.3. *minor isomer:* ¹H NMR (395 MHz, CDCl₃) δ 1.23-1.50 (m, 4H), 1.53-1.81 (m, 4H), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz, CDCl₃) δ 1.23-1.50 (m, 4H), 1.53-1.81 (m, 4H), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (67.8 MHz), 2.21-2.47 (m, 4H), 2.94 (s, 3H), 3.65 (s, 3H), 4.53 (s, 2H), 7.11-7.41 (m, 5H); ¹³C NMR (s, 2H), 3.51 (s, 2H), 3.51 (s, 2H), 7.1

MHz, CDCl₃) δ 24.8, 25.2, 28.9, 29.1, 33.0, 33.9, 34.9, 51.5, 53.4, 127.3, 127.6, 128.9, 136.8, 173.5, 174.2.

N-Benzyl-*N*-methyl-4-oxo-pentanamide (1g): This compound was prepared from levulinic acid and pivaloyl chloride followed by the reaction with benzylmethylamine. IR (neat) v 2919, 1715, 1646, 1450, 1402, 1369, 1164, 731, 700 cm⁻¹; HRMS (EI) calcd for C₁₃H₁₇NO₂ 219.1259, found 219.1260. Spectroscopic data of this amide were obtained as a mixture of two rotational isomers. *major isomer:* ¹H NMR (395 MHz, CDCl₃) δ 2.24 (s, 3H), 2.65 (t, *J* = 6.3 Hz, 2H), 2.84 (t, *J* = 6.3 Hz, 2H), 2.95 (s, 3H), 4.58 (s, 2H), 7.19-7.41 (m, 5H); ¹³C NMR (99.5 MHz, CDCl₃) δ 27.0, 29.8, 34.3, 37.72, 50.5, 126.1, 127.5,

128.2, 137.0, 171.3, 207.4. *minor isomer:* ¹H NMR (395 MHz, CDCl₃) δ 2.23 (s, 3H), 2.66 (t, J = 6.3 Hz, 2H), 2.80 (t, J = 6.3 Hz, 2H), 2.93 (s, 3H), 4.57 (s, 2H), 7.19-7.41 (m, 5H); ¹³C NMR (99.5 MHz, CDCl₃) δ 26.7, 29.7, 33.5, 37.70, 52.7, 126.9, 127.2, 128.5, 136.2, 171.5, 207.3.

Citronellic acid *N*-benzyl-*N*-methylamide (1h):^{1c} This compound was prepared from citronellic CONMeBn acid and pivaloyl chloride followed by the reaction with *N*-methylbenzylamine. IR (neat) v 2962, 2923, 1649, 1452, 1401, 1262,

1118, 1077, 733 cm⁻¹; Spectroscopic data of this amide were obtained as a mixture of two rotational isomers. *major isomer*: ¹H NMR (600 MHz, CDCl₃) δ 0.98 (d, *J* = 6.6 Hz, 3H), 1.21 (m, 1H), 1.40 (m, 1H), 1.60 (s, 3H), 1.67 (s, 3H), 1.90-2.11 (m, 3H), 2.19 (dd, *J* = 14.8, 8.8 Hz, 1H), 2.37 (dd, *J* = 14.8, 5.5 Hz, 1H), 2.91 (s, 3H), 4.60 (s, 2H), 5.10 (t, *J* = 7.1 Hz, 1H), 7.14-7.37 (m, 5H); ¹³C NMR (150 MHz, CDCl₃) δ 19.8, 25.5, 25.7, 27.1, 30.0, 34.9, 37.1, 40.7, 50.7, 124.4, 127.2, 128.0, 128.5, 131.3, 137.6, 172.7. *minor isomer*: ¹H NMR (600 MHz, CDCl₃) δ 0.95 (d, *J* = 6.6 Hz, 3H), 1.21 (m, 1H), 1.40 (m, 1H), 1.57 (s, 3H), 1.65 (s, 3H), 1.90-2.11 (m, 3H), 2.20 (dd, *J* = 14.8, 7.7 Hz, 1H), 2.36 (dd, *J* = 14.8, 5.5 Hz, 1H), 2.93 (s, 3H), 4.52 (d, *J* = 16.5 Hz, 1H), 4.54 (d, *J* = 16.5 Hz, 1H), 5.07 (t, *J* = 7.1 Hz, 1H), 7.14-7.37 (m, 5H); ¹³C NMR (150 MHz, CDCl₃) δ 17.6, 25.5, 25.6, 28.4, 30.0, 33.8, 37.0, 40.4, 53.4, 124.5, 126.2, 127.5, 128.8, 131.3, 136.7, 173.1.

(*E*)-1-(morpholine-4-yl)-3-hexen-1-one (1i): This compound was prepared from (*E*)-3-hexenoyl chloride and morpholine. IR (neat) v 2967, 2849, 1644, 1434, 1277, 1229, 1115, 1034, 974, 745 cm⁻¹; ¹H NMR (395 MHz, CDCl₃) δ 0.99 (t, *J* = 7.3 Hz, 3H), 2.00-2.11 (m, 2H), 3.08 (d, *J* = 5.8 Hz, 2H), 3.42-3.50 (m, 2H), 3.57-3.71 (m, 6H), 5.47-5.64 (m, 2H): ¹³C NMR (99.5 MHz, CDCl₃) δ 13.2, 25.1, 37.0, 41.5, 45.8, 66.2

3.71 (m, 6H), 5.47-5.64 (m, 2H); ¹³C NMR (99.5 MHz, CDCl₃) δ 13.2, 25.1, 37.0, 41.5, 45.8, 66.2, 66.4, 121.1, 135.2, 169.6; HRMS (EI) calcd for C₁₀H₁₇NO₂ 183.1259, found 183.1254.

3. General Procedure for the Reduction/Dehydration of Carboxamides.

IrCl(CO)(PPh₃)₂/TMDS (Table 2): To a 0.1 *M* solution of IrCl(CO)(PPh₃)₂ in toluene (0.5 mL; 0.05 mmol of [Ir]) was added the substrate (1 mmol) and TMDS (268 mg, 2.0 mmol) at 25 °C. After it was stirred at 25 °C for 30 min, the solvent was removed under reduced pressure. The conversion of the substrate and the chemical yields of both enamine and amine were determined by capillary GLC (hexamethylbenzeene as an internal standard) or ¹H NMR (ferrocene or tetrachloroethane as an internal standard) analysis. *Isoration of Enamines (2a-c and 2i):* After the reaction was completed, a solution of KOH in MeOH (3.8 *M*, 5 mL) was added to the reaction mixture and resultant solution was stirred at 25 °C for 30 min. After the solvent was removed under reduced pressure, the resultant residue was washed five times with ether (totally 30 mL). The combined organic solution was filtered through a pad of Celite and the filtrate was evaporated under reduced pressure to give the enamines (**2a-c** and **2i**). **2a:** 149 mg (85%); **2b:** 180 mg (86%); **2c:** 155 mg (82%); **2i:** 144 mg (86%). *Isolation of Enamine 2d:* After the reaction was concentrated under reduced pressure. Purification by silica gel chromatography [ether-hexane (containing 1% of Et₃N)] gave phenylacetaldehyde (70%) and **2d** (23%).

IrCl(CO)(PPh₃)₂/PMHS (Table 3): To a 0.2 *M* solution of IrCl(CO)(PPh₃)₂ in toluene (0.5 mL; 0.01 mmol of [Ir]) was added the substrate (1 mmol) and PMHS (266 mg, Si–H = 4.0 mmol) at 25 °C. The homogeneous solution turns to gel after 15 min. After it was allowed to stand for 15 min, the resultant residue was washed ten times with ether (totally 30 mL), and the combined organic solution was filtered through a pad of Celite and the filtrate was evaporated under reduced pressure.
2b: 199 mg (95%); 2c: 180 mg (95%); 2d: 152 mg (90%); 2f: 237 mg (86%); 2h: 247 mg (96%); 2i: 164 mg (98%).

ICP-MS Analysis of the Product: The iridium content in enamines was determined by ICP-MS analysis: enamine **2c** obtained by the above procedure was dissolved in an aqueous solution of HCl, and the concentration of HCl was adjusted to 5×10^{-3} wt%. The content of **2** in this solution was 6.2 x 10^{-3} mol/L. The measurement was performed using this solution. The iridium content was calibrated with a commercially available standard reagent (ACROS: iridium atomic absorption standard solution, 1 mg/mL Ir in 5% HCl); five standard solutions, of which Ir concentration is in a range from 5ppb to 200ppb, were used for calibration. In both cases, the Ir content was bellow identification limit.

Various Transition Metal Catalysts/TMDS: To a solution of catalyst (0.001 mmol, 0.1 mol%) in toluene (0.5 mL) was added TMDS (268 mg, 2.0 mmol) through a microsyringe and the mixture was stirred at 25 °C for 30 min followed by addition of *N*,*N*-diethylphenylacetamide **1a** (191 mg, 1 mmol). After it was stirred at 25 °C for 4 h, the solvent was removed under reduced pressure. The conversion of **1a** and the chemical yields of both enamine **2a** and amine **3** were determined by capillary GLC analysis with hexamethylbenzeene as an internal standard. GLC (TC-1, 30 m, detection FID, column temp. 170 °C), $t_{\rm R} = 6.6 \min(3)$, 10.3 min (**2a**), 11.7 min (**1a**).



	yield (%) ^a			yield $(\%)^a$	
catalyst	enamine 2a	amine 3	catalyst	enamine 2a	amine 3
Ru ₃ (CO) ₁₂	<1	<1	RhCl(PPh ₃) ₃	3	<1
(ACE)Ru ₃ (CO) ₇	13	4	$[RhCl(cod)_2]_2$	11	<2
$(ACE)Ru_3(CO)_7^b$	54	46			
PtCl ₂ (cod)	43	8	IrCl ₃ · H ₂ O	<1	<1
$Pt(dba)_2$	38	6	$[IrCl(cod)_2]_2$	3	<1
Karstedt's cat.	41	7	$IrCl(CO)(PPh_3)_2^c$	96	<1

Table S-1. Reaction of 1a with TMDS catalyzed by various transition metal catalysts.

^{*a*} Determined by GLC analysis. ^{*b*} 1 mol% of catalyst was used. ^{*c*} For 30 min.

IrCl(CO)(PPh₃)₂/Various Hydrosilanes: To a 0.2 *M* solution of IrCl(CO)(PPh₃)₂ in toluene (0.5 mL, 0.01 mmol of [Ir]) was added hydrosilane (Si–H = 4.0 mmol) through a microsyringe and the mixture was stirred at 25 °C for 30 min followed by addition of *N*,*N*-diethylphenylacetamide **1a** (191 mg, 1 mmol). After it was stirred at 25 °C for 4 h, the solvent was removed under reduced pressure. The conversion of **1a** and the chemical yields of both enamine **2a** and amine **3** were determined by capillary GLC analysis with hexamethylbenzeene as an internal standard.



Table S-2. Reaction of 1a with various hydrosilanes catalyzed by IrCl(CO)(PPh₃)₂.

	yield (%)		1 1 1	yield $(\%)^a$	
hydrosilane	2a	3	hydrosilanev	2a	3
Et ₃ SiH	<1	<1	Ph ₂ SiH ₂	<1	<1
PhMe ₂ SiH	3	<1		~1	~1
TMSOSiMe ₂ H	5	<1		<1	<1
H H (0.1 mol%)	>99	<1			
Me ₂ Si _O SiMe ₂ (0.05 mol%)	96	<1	$ \qquad \qquad$	<1	<1
(30 min) (0.01 mol%)	82	<1			

IrCl(CO)(PPh₃)₂/PMHS; Solvent Effects: To a 0.02 *M* solution of IrCl(CO)(PPh₃)₂ in solvent (0.5 mL, 0.1 mmol of [Ir]) was added PMHS (266 mg, Si–H = 4.0 mmol) through a microsyringe and the mixture was stirred at 25 °C for 30 min followed by addition of *N*,*N*-diethylphenylacetamide **1a** (1 mmol). The homogeneous solution turns to gel after 15 min. After it was allowed to stand for 15 min, the resultant residue was washed ten times with ether (totally 30 mL), and the combined organic solution was evaporated under reduced pressure. The conversion of **1a** and the chemical yields of both enamine **2a** and amine **3** were determined by capillary GLC analysis with hexamethylbenzeene as an internal standard.

∧ NEt	[Me H]	IrCl(CO)(PPh ₃) ₂ (0.1 mol%)		
Ph +		solvent (0.5 mL)	Ph NEt ₂	+ Ph NEt ₂
1a: 1 mmol	Si-H = 4 mmol	25 °C, 30 min	2a	3

Table S-3. The reaction of 1a with PMHS catalyzed by IrCl(CO)(PPh₃)₂.

solvent	conversion (%)	yield (%)		selectivity
	—	enamine 2a	amine 3	(% enamine)
toluene	>99	93	7	93.0
benzene	>99	91	7	92.8
xylene	>99	85	15	85.0
Et_2O	>99	91	9	91.0
THF	>99	88	11	88.9
CH_2Cl_2	>99	82	18	82.0

4. Spectral Data of Enamines.

(*E*)-*N*,*N*-Diethylstyrylamine (2a):⁹ IR (neat) v 2961, 2931, 1635, 1594, 1403, 1260, 1110, 937, Ph \sim NEt₂ $= 7.8 \text{ cm}^{-1}$; ¹H NMR (270 MHz, CDCl₃) δ 1.15 (t, *J* = 7.3 Hz, 6H), 3.16 (q, *J* = 7.3 Hz, 4H), 5.16 (d, *J* = 14.1 Hz, 1H), 6.75 (d, *J* = 14.1 Hz, 1H), 6.93 (tt, *J* = 6.6, 2.3 Hz, 1H), 7.10-7.23 (m, 4H); ¹³C NMR (67.8 MHz, CDCl₃) δ 13.3, 45.3, 96.1, 122.7, 123.1, 128.4, 137.6, 140.2; GLC (TC-1, 30 m, detection FID, column temp. 170 °C), *t*_R = 10.3 min.

(*E*)-*N*-Methyl-*N*-phenylstyrylamine (2b):^{10a} IR (neat) v 3057, 3024, 2896, 1638, 1592, 1497, Ph NMePh 1343, 1257, 1127, 936, 753 cm⁻¹; ¹H NMR (396 MHz, CDCl₃) δ 3.29 (s, 3H), 5.66 (d, *J* = 14.0 Hz, 1H), 6.98 (t, *J* = 7.3 Hz, 1H), 7.03-7.10 (m, 3H), 7.13-7.39 (m, 7H); ¹³C NMR (67.8 MHz, CDCl₃) δ 35.6, 103.6, 117.9, 121.4, 124.3, 124.4, 128.7, 129.4, 134.1, 139.0, 147.7.

(*E*)-4-Styrylmorpholine (2c):¹⁰ IR (KBr) v 2964, 2828, 1637, 1594, 1439, 1379, 1227, 1115, 1018, 0 937, 811 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.04 (t, *J* = 4.9 Hz, 4H), 3.77 (t, *J* = 4.9 Hz, 4H), 5.44 (d, *J* = 14.2 Hz, 1H), 6.62 (d, *J* = 14.2 Hz, 1H), 7.04 (t, *J* = 6.3 hz, 1H), 7.16-7.28 (m, 4H); ¹³C NMR (99.5 MHz, CDCl₃) δ 49.1, 66.5, 101.6, 124.3, 124.5, 128.6, 138.7, 139.7; HRMS (EI) calcd for C₁₂H₁₅NO 189.1154, found 189.1153; GLC (TC-1, 30 m, detection FID, column temp. 170 °C), *t*_R = 15.5 min.

(*E*)-4-(1-Hexenyl)morpholine (2d):¹¹ IR (neat) v 2957, 2923, 2854, 1655, 1450, 1379, 1260, 1160, N 1121, 1014, 939, 865 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 0.87 (t, *J* = 6.9 Hz, 3H), 1.20-1.37 (m, 4H), 1.95 (td, *J* = 7.3, 6.9 Hz, 2H), 2.75 (t, *J* = 4.9 Hz, 4H), 3.70 (t, *J* = 4.9 Hz, 4H), 4.45 (dt, *J* = 13.9, 6.9 Hz, 1H), 5.78 (d, *J* = 13.9 Hz, 1H); ¹³C NMR (67.8 MHz, CDCl₃) δ 14.0, 22.1, 30.1, 33.4, 49.6, 66.6, 103.1, 139.5; GLC (TC-1, 30 m, detection FID, column temp. 170 °C), *t*_R = 6.0 min.

(*E*)-4-(6-Bromo-1-hexenyl)morpholine (2e): ¹H NMR (270 MHz, CDCl₃) δ 1.37-1.56 (m, 2H), 1.78-1.93 (m, 2H), 2.00 (td, *J* = 7.3, 6.9 Hz, 2H), 2.77 (t, *J* = 4.9 Hz, 4H), 3.41 (t, *J* = 6.9 Hz, 2H), 3.72 (t, *J* = 4.9 Hz, 4H), 4.41 (dt, *J* = 13.9, 6.9 Hz, 1H), 5.81 (d, *J* = 13.9 Hz, 1H); ¹³C NMR (67.8 MHz, CDCl₃) δ 29.5, 29.6, 32.2, 34.0, 49.5, 66.6, 101.8, 140.0; HRMS (EI) calcd for C₁₀H₁₈BrNO 247.0572, found 247.0571.

(E)-N-Benzyl-N-methyl-7-carbomethoxy-1-heptenylamine (2f): IR (neat) v 2931, 2853, 1728, MeO₂C NBnMe 1653, 1453, 1373, 1259, 1119, 1073, 738, 699 cm⁻¹; ¹H NMR (396 MHz, CDCl₃) δ 1.23-1.35 (m, 4H), 1.52-1.63 (m, 2H), 1.94 (dt, J = 7.2, 6.3 Hz, 2H), 2.26 (t, J = 7.2 Hz, 2H), 2.44 (s, 3H), 3.62 (s, 3H), 3.96 (s, 2H), 4.16 (dt, J = 13.5, 7.2 Hz, 1H),

6.04 (d, J = 13.5 Hz, 1H), 7.15-7.29 (m, 5H); ¹³C NMR (67.8 MHz, CDCl₃) δ 24.9, 28.6, 30.3, 31.2, 34.2, 36.6, 51.4, 59.2, 99.0, 127.0, 127.9, 128.3, 138.8, 139.4, 174.3; HRMS (EI) calcd for C₁₇H₂₅NO₂ 275.1885, found 275.1888.

N-Benzyl-*N*-methyl-4-oxo-1-pentenylamine (2g): ¹H NMR (396 MHz, CDCl₃) δ 2.13 (s, 3H), O NBnMe NBnMe 2.56 (s, 3H), 3.03 (d, J = 7.2 Hz, 2H), 4.07 (s, 2H), 4.20 (dt, J = 13.5, 7.2 Hz, 1H), 6.17 (d, J = 13.5 Hz, 1H), 7.18-7.35 (m, 5H); ¹³C NMR (99.5 MHz, CDCl₃) δ 36.6, 45.8, 59.0, 67.9, 89.1, 127.2, 127.7, 128.5, 138.5, 142.2, 209.2; HRMS (EI) calcd for C₁₃H₁₇NO 203.1310, found 203.1304.

N-Benzyl-*N*-methyl-3,7-dimethyl-oct-1,6-dienylamine (2h): IR (neat) v 2961, 2918, 2860, 1651, *NBnMe* 1453, 1375, 1260, 1198, 1059, 935, 735, 698 cm⁻¹; ¹H NMR (396 MHz, CDCl₃) δ 1.00 (d, *J* = 6.8 Hz, 3H), 1.19-1.40 (m, 2H), 1.61 (bs, 3H), 1.69 (bs, 3H), 1.88-2.13 (m, 3H), 2.48 (s, 3H), 4.02 (s, 2H), 4.10 (dd, *J* = 14.0, 8.2 Hz, 1H), 5.12 (tm, *J* = 7.2 Hz, 1H), 6.05 (d, *J* = 14.0 Hz, 1H), 7.21-7.35 (m, 5H); ¹³C NMR (99.5 MHz, CDCl₃) δ 17.8, 22.8, 25.8, 26.1, 34.8, 36.7, 28.9, 59.3, 106.1, 125.3, 127.0, 128.0, 128.4, 130.9, 138.2, 138.9; HRMS (EI) calcd for C₁₈H₂₇N 257.2143, found 257.2147.

(*E,E*)-4-(1,3-Hexadienyl)morpholine (2i): IR (neat) v 2961, 2853, 1648, 1454, 1433, 1270, 1117, 970, 907 cm⁻¹; ¹H NMR (396 MHz, CDCl₃) δ 0.98 (t, *J* = 7.5 Hz, 3H), 2.06 (qd, *J* = 7.5, 6.8 Hz, 2H), 2.88 (t, *J* = 4.8 Hz, 4H), 3.71 (t, *J* = 4.8 Hz, 4H), 5.21 (dd, *J* = 13.5, 10.1 Hz, 1H), 5.41 (dt, *J* = 15.5, 6.8 Hz, 1H), 5.94 (dd, *J* = 15.5, 10.1 Hz, 1H), 6.03 (d, *J* = 13.5 Hz, 1H); ¹³C NMR (99.5 MHz, CDCl₃) δ 14.3, 25.9, 49.1, 66.5, 103.1, 128.06, 128.11, 141.1. ¹³C NMR (99.5 MHz, C₆D₆) δ 14.6, 26.4, 49.1, 66.3, 103.5, 127.2, 129.3, 141.4. HRMS (EI) calcd for C₁₀H₁₇NO 167.1310, found 167.1317.

5. Cyclopropanation of 2b. To a solution of 2b (Table 3. entry 3; 201 mg) in benzene (2 mL) was added 1.2 mL of Et₂Zn in hexane (1.0 *N*; 1.2 mmol of Et₂Zn) at 0 °C. To the mixture was added CH₂I₂ (97 μ L, 1.2 mmol) dropwise at that temperature. The resultant yellow suspension was gradually warmed to ambient temperature and then was allowed to further stir for 2 h. The reaction mixture was diluted with ether (4 mL) and then quenched by addition of 10% aqueous NH₄OH solution (4 mL). The organic layer was separated and dried over MgSO₄. Purification by silica gel chromatography (hexane/ether = 9:1) gave *trans-N*-(2-phenylcyclopropyl)-*N*-methylaniline (4) in 61% yield (136 mg).

trans-N-(**2-Phenylcyclopropyl**)-*N*-methylaniline (4): IR (neat) v 3026, 2930, 2871, 1600, 1502, Ph \searrow_{N} Ph 1340, 1115, 910, 753, 695 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 1.30-1.38 (m, 2H), Me 2.08 (ddd, J = 9.6, 6.6, 3.3 Hz, 1H), 2.59 (m, 1H), 3.04 (s, 3H), 6.77 (t, J = 7.1 Hz, 1H), 6.88 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.7 Hz, 2H), 7.20-7.25 (m, 3H), 7.33 (dd, J = 7.7, 7.4 Hz, 2H); ¹³C NMR (67.8 MHz, CDCl₃) δ 18.8, 27.5, 38.7, 44.1, 113.9, 117.7, 125.9, 126.0, 128.5, 129.0, 141.2, 150.4; HRMS (EI) calcd for C₁₆H₁₇N 223.1361, found 223.1360.

6. References

- (a) H. Nagashima, T. Fukahori, K. Aoki and K. Itoh, J. Am. Chem. Soc., 115, 10430 (1993); (b)
 Y. Motoyama, C. Itonaga, T. Ishida, M. Takasaki and H. Nagashima, Org. Synth., 82, 188 (2005); (c) S. Hanada, Y. Motoyama and H. Nagashima, Tetrahedron Lett., 47, 6173 (2006).
- 2 (a) K. Vrieze, J. P. Collman, C. T. Sears, Jr. and M. Kubota, *Inorg. Synth.*, 11, 101 (1968); (b) J. A. Osborn and G. Wilkinson, *Inorg. Synth.*, 10, 67 (1967); (c) G. Giordano and R. H. Crabtree, *Inorg. Synth.*, 19, 218 (1979); (d) W. J. Cherwinski, B. F. G. Johnson and J. Lewis, *J. Chem. Soc.*, *Dalton Trans.*, 1405 (1974); (e) J. X. McDermott, J. F. White and G. M. Whitesides, *J. Am. Chem. Soc.*, 98, 6521 (1976); (f) P. Pawluc, B. Marciniec, I. Kownacki and H. Maciejewski, *Appl. Organometal. Chem.*, 19, 49 (2005); (g) S. Hanada, Y. Motoyama and H. Nagashima, *Eur. J. Org. Chem.*, 4097 (2008).
- 3 (a) R. Mukherjee, J. Chem. Soc., Chem. Commun., 1113 (1971); (b) T. Imamoto, T. Kusumoto and M. Yokoyama, Bull. Chem. Soc. Jpn., 55, 643 (1982).
- 4 R. A. Rossi and R. A. Alonso, J. Org. Chem., 45, 1239 (1980).
- 5 A. H. Schlesinger and E. J. Prill, J. Am. Chem. Soc., 78, 6123 (1956).
- 6 M. Badioli, R. Ballini, M. Bartolacci, G. Bosica, E. Torregiani and E. Marcantoni, J. Org. Chem., 67, 8938 (2002).
- 7 J. H. Kirchhoff, M. R. Netherton, I. D. Hills and G. C. Fu, J. Am. Chem. Soc., **124**, 13662 (2002).
- 8 H. Sasakuma, Y. Motoyama and H. Nagashima, *Chem. Commun.*, 4916 (2007).
- 9 A. Tillack, H. Trauthwein, C. G. Hartung, M. Eichberger, A. Jansen and M. Beller, *Monatsh. Chemie*, 131, 1327 (2000).
- 10 (a) J. Barlnenga, M. A. Fernández, F. Aznar and C. Valdés, *Chem. Eur. J.*, 10, 494 (2004); (b) G. Bélanger, M. Doré, F. Ménard and V. Darsigny, *J. Org. Chem.*, 71, 7481 (2006).
- 11 M. Ahmed, A. M. Seayad, R. Jackstell and M. Beller, Angew. Chem. Int. Ed., 42, 5615 (2003).

7. NMR Spectra of Enamines and Cyclopropanation Product 4

(E)-N,N-Diethyl-styrylamine (2a) : Table 2, Entry 1



(E)-4-(1-Hexenyl)morpholine (2d) : Table 3, Entry 4



(E)-4-(6-Bromo-1-hexenyl)morpholine (2e) : Table 2, Entry 5



(E)-N-Benzyl-N-methyl-7-carbomethoxy-1-heptenylamine (2f): Table 3, Entry 6



N-Benzyl-N-methyl-4-oxo-1-pentenylamine (2g) : Table 2, Entry 7



N-Benzyl-*N*-methyl-3,7-dimethyl-oct-1,6-dienylamine (2h) : Table 3, Entry 7



(E,E)-4-(1,3-Hexadienyl)morpholine (2i) : Table 3, Entry 10



trans-N-(2-Phenylcyclopropyl)-N-methylaniline (4)

